Hematopathology — MCQs

Hematopathology Indian Medical PG Practice Questions and MCQs

Question 1161: What is the condition characterized by a normal or decreased leukocyte count in the peripheral blood, yet still showing white blood cells?

A. Aleukemic Leukemia (Correct Answer)
B. Subleukemic leukemia
C. Acute leukemia
D. Chronic leukemia

Explanation: ### Explanation The classification of leukemia based on peripheral blood findings is a high-yield topic for NEET-PG. The distinction between "Aleukemic" and "Subleukemic" leukemia depends on the total leukocyte count (TLC) and the presence of abnormal cells. **1. Why Aleukemic Leukemia is Correct:** **Aleukemic leukemia** is defined by two criteria: * The **Total Leukocyte Count (TLC)** is either normal or decreased (leukopenia). * **Abnormal/Blast cells are absent** or extremely rare in the peripheral blood smear. The diagnosis is made by examining the bone marrow, which will be hypercellular and packed with leukemic blasts. The question describes a scenario where the count is low/normal but the disease (leukemia) is present. **2. Why the Other Options are Incorrect:** * **Subleukemic Leukemia:** In this condition, the TLC is also low or normal (similar to aleukemic), but **abnormal/blast cells are visible** in the peripheral blood smear. * **Acute Leukemia:** This is a broad clinical category characterized by a rapid increase in immature blast cells. While it can present as aleukemic, most cases present with a high TLC (leukocytosis). * **Chronic Leukemia:** These typically present with significantly elevated TLC (often >100,000/µL) and a spectrum of maturing cells, not a low or normal count. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Dry Tap":** Aleukemic leukemia often presents with a "dry tap" on bone marrow aspiration due to intense marrow packing (hypercellularity), necessitating a bone marrow biopsy. * **Pancytopenia Differential:** Always consider aleukemic leukemia in the differential diagnosis of a patient presenting with pancytopenia (anemia, neutropenia, and thrombocytopenia). * **Terminology Tip:** * *Leukemic:* High TLC + Blasts in blood. * *Subleukemic:* Low/Normal TLC + Blasts in blood. * *Aleukemic:* Low/Normal TLC + **No** Blasts in blood.

Question 1162: What is a condition characterized by a deficiency in globin synthesis?

A. Thalassemia (Correct Answer)
B. Sickle cell disease
C. Hereditary spherocytosis
D. None of these

Explanation: **Explanation:** **Thalassemia** is the correct answer because it is defined as a **quantitative defect** in hemoglobin synthesis [1]. It involves a reduced rate of production or total absence of one or more of the globin polypeptide chains ($\alpha$ or $\beta$) [2]. This imbalance leads to ineffective erythropoiesis and hemolysis [3]. **Analysis of Options:** * **Sickle Cell Disease (Option B):** This is a **qualitative defect** (hemoglobinopathy) [1]. It results from a point mutation in the $\beta$-globin gene (substitution of valine for glutamic acid at the 6th position), leading to the production of abnormal Hemoglobin S (HbS), rather than a deficiency in the amount of globin produced. * **Hereditary Spherocytosis (Option C):** This is a red cell **membrane defect**. It is caused by mutations in proteins that link the membrane skeleton to the lipid bilayer (most commonly **Ankyrin**, followed by Spectrin or Band 3), leading to spherical, fragile RBCs. * **None of these (Option D):** Incorrect, as Thalassemia directly fits the description. **High-Yield NEET-PG Pearls:** * **Thalassemia = Quantitative** (Less globin); **Sickle Cell = Qualitative** (Bad globin) [1]. * **Microscopy:** Thalassemia typically shows **Target cells** (codocytes) and microcytic hypochromic anemia. * **Mentzer Index:** Used to differentiate Iron Deficiency Anemia (IDA) from Thalassemia trait. A ratio of MCV/RBC count **< 13** suggests Thalassemia, while **> 13** suggests IDA. * **Hb Electrophoresis:** The gold standard for diagnosis (e.g., increased **HbA2** in $\beta$-Thalassemia minor) [4]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 587-588. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 646-647. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 647-648. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, p. 650.

Question 1163: A patient's Prothrombin Time (PT) is 26 seconds, the control PT is 13 seconds, and the sensitivity index is 1.41. Calculate the patient's International Normalized Ratio (INR).

A. 26/13
B. (26/13) x 1.41
C. (26/13) + 1.41
D. (26/13) ^ 1.41 (Correct Answer)

Explanation: ### Explanation **1. Understanding the Correct Answer (Option D)** The International Normalized Ratio (INR) was developed to standardize Prothrombin Time (PT) results across different laboratories, accounting for variations in the sensitivity of the thromboplastin reagents used. The mathematical formula for INR is: **INR = (Patient’s PT / Control PT) ^ ISI** * **Patient’s PT:** 26 seconds * **Control PT:** 13 seconds * **ISI (International Sensitivity Index):** 1.41 (This represents the responsiveness of the specific thromboplastin compared to an international standard). Plugging the values into the formula: **INR = (26/13) ^ 1.41**. This exponential relationship ensures that the result is normalized regardless of the reagent's potency. **2. Why Other Options are Incorrect** * **Option A:** This is simply the **Prothrombin Ratio (PR)**. It fails to account for the reagent sensitivity (ISI), leading to inconsistent results between labs. * **Option B & C:** These represent incorrect mathematical operations (multiplication and addition). The ISI must be applied as an **exponent** to correctly normalize the ratio. **3. Clinical Pearls for NEET-PG** * **Pathway:** PT/INR assesses the **Extrinsic** and **Common** pathways (Factors VII, X, V, II, and I) [2]. * **Monitoring:** INR is the gold standard for monitoring **Warfarin (Oral Anticoagulant)** therapy [1]. * **Target INR:** Usually **2.0–3.0** for most conditions (e.g., Atrial Fibrillation, DVT); **2.5–3.5** for mechanical heart valves. * **Vitamin K:** Factors II, VII, IX, and X are Vitamin K dependent [1]. Factor VII has the shortest half-life, making PT/INR the first lab value to prolong in Vitamin K deficiency or early liver disease [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 582-583. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 128-130.

Question 1164: Which of the following findings are typically visualized using a Romanowsky stain?

A. Reticulocytes and Basophilic stippling
B. Basophilic stippling and Heinz bodies
C. Reticulocytes and Cabot rings
D. Reticulocytes and Howell-Jolly bodies (Correct Answer)

Explanation: **Explanation:** Romanowsky stains (e.g., Leishman, Giemsa, Wright stains) are the standard polychromatic stains used for routine peripheral blood smears. They consist of Methylene blue (basic) and Eosin (acidic) dyes, which allow for the visualization of various intracellular inclusions based on their pH. **Why Option D is Correct:** * **Howell-Jolly bodies:** These are nuclear remnants (DNA) seen as small, round, purple-blue inclusions [1]. Since DNA is acidic, it reacts with the basic component of Romanowsky stains, making them clearly visible [1]. * **Reticulocytes:** While a definitive reticulocyte count requires **Supravital stains** (like New Methylene Blue) to visualize the RNA network, reticulocytes can be identified on a Romanowsky stain as **polychromatic cells** (larger cells with a bluish-grey hue) [1]. Therefore, they are "visualized," albeit indirectly, as polychromasia. **Analysis of Incorrect Options:** * **Basophilic stippling (Options A & B):** These are fine or coarse blue granules representing precipitated ribosomes (RNA). They are visible on Romanowsky stains. * **Heinz Bodies (Option B):** These represent denatured hemoglobin. They are **not visible** on Romanowsky stains and require Supravital stains (e.g., Crystal violet) for visualization. * **Cabot Rings (Option C):** These are thin, red-purple thread-like loops (microtubule remnants) seen in megaloblastic anemia. While visible on Romanowsky stains, they are often paired with reticulocytes in these options to test the distinction between routine and supravital requirements. **High-Yield Clinical Pearls for NEET-PG:** * **Supravital Stains:** Required for **Heinz bodies** (G6PD deficiency) and **Reticulocyte networks**. * **Howell-Jolly bodies:** Classically seen post-splenectomy or in functional asplenia (Sickle Cell Anemia). * **Basophilic stippling:** Classically associated with **Lead poisoning** (coarse) and Thalassemias (fine). * **Pappenheimer bodies:** Siderotic granules (Iron) visible on Romanowsky stains but confirmed with **Perls' Prussian Blue**. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 578-579.

Question 1165: Retention of mature neutrophils in bone marrow is known as:

A. Myelokathesis (Correct Answer)
B. Myelocytosis
C. Leukocytosis
D. Leukemia

Explanation: **Explanation:** **1. Why Myelokathesis is correct:** **Myelokathesis** (from the Greek *myelo* meaning marrow and *kathesis* meaning retention) is a rare congenital disorder characterized by severe chronic leukopenia and neutropenia. The underlying pathophysiology involves a mutation in the **CXCR4 receptor** gene. Normally, the interaction between CXCR4 on neutrophils and CXCL12 (SDF-1) in the bone marrow keeps precursors in the niche; a "gain-of-function" mutation causes excessive signaling, preventing mature neutrophils from exiting the marrow into the peripheral blood. On a bone marrow aspirate, this manifests as hypercellularity with an abundance of mature, often apoptotic-looking neutrophils (senescent changes like pyknotic nuclei and long filaments connecting nuclear lobes). **2. Why other options are incorrect:** * **Myelocytosis:** This is a general term referring to an increase in myeloid cells (specifically myelocytes) in the blood or bone marrow, often seen in leukemoid reactions or CML. * **Leukocytosis:** This refers to an elevated white blood cell count in the peripheral blood, which is the opposite of what occurs in myelokathesis. * **Leukemia:** This is a malignant proliferation of hematopoietic stem cells leading to the replacement of normal marrow with neoplastic cells (blasts or mature cells), not a retention defect of normal mature cells. **3. High-Yield Clinical Pearls for NEET-PG:** * **WHIM Syndrome:** Myelokathesis is a key component of the WHIM syndrome triad: **W**arts (HPV), **H**ypogammaglobulinemia, **I**nfections, and **M**yelokathesis. * **Genetics:** Look for **CXCR4** gene mutations in clinical vignettes. * **Morphology:** "Hypersegmented" or "pyknotic" neutrophils in a hypercellular marrow despite peripheral neutropenia is the classic diagnostic clue.

Question 1166: Histiocytic necrotizing lymphadenitis is:

A. Kimura disease
B. Kikuchi disease (Correct Answer)
C. Hodgkin's disease
D. Castleman's disease

Explanation: **Explanation:** **Kikuchi disease**, also known as **Kikuchi-Fujimoto disease** or **Histiocytic Necrotizing Lymphadenitis**, is a benign, self-limiting condition typically affecting young women. It clinically presents with fever and painful cervical lymphadenopathy, often mimicking lymphoma or tuberculosis. 1. **Why B is correct:** The hallmark histopathology of Kikuchi disease is **circumscribed necrosis** in the paracortical areas of the lymph node. Key features include an abundance of **karyorrhectic debris** (nuclear dust) and a proliferation of **plasmacytoid dendritic cells** and histiocytes. Crucially, there is a **conspicuous absence of neutrophils**, distinguishing it from bacterial lymphadenitis. 2. **Why other options are incorrect:** * **Kimura disease:** A chronic inflammatory condition characterized by painless lymphadenopathy, peripheral eosinophilia, and elevated IgE levels. Histology shows lymphoid follicles with prominent eosinophilic infiltrates. * **Hodgkin’s disease:** A malignancy characterized by the presence of **Reed-Sternberg (RS) cells** in a background of reactive inflammatory cells. It does not present as primary necrotizing histiocytic inflammation. * **Castleman’s disease:** Also known as Angiofollicular Lymph Node Hyperplasia. The "Hyaline-vascular" type shows "lollipop" follicles (atrophic germinal centers with penetrating vessels), while the "Plasma cell" type shows sheets of plasma cells. **High-Yield Clinical Pearls for NEET-PG:** * **Demographics:** Most common in young Asian females (age <40). * **Pathology Keyword:** "Karyorrhectic debris" + "Crescentic histiocytes" + "Absence of neutrophils." * **Differential Diagnosis:** Must be differentiated from **Systemic Lupus Erythematosus (SLE)** lymphadenopathy, which looks similar but contains "Hematoxylin bodies" and plasma cells [1]. * **Prognosis:** Excellent; usually resolves spontaneously within 1–4 months. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 554-555.

Question 1167: Del(1;?) or D(1;?) translocation is common in which subtype of acute myeloid leukemia (AML)?

A. Monocytic (M5)
B. Promyelocytic (M3) (Correct Answer)
C. Erythrocytic (M6)
D. Megakaryocytic (M7)

Explanation: **Acute Promyelocytic Leukemia (AML-M3)** is classically defined by the reciprocal translocation **t(15;17)(q22;q12)**, involving the *PML* and *RARA* genes [1]. However, cytogenetic studies have shown that **der(1) or del(1)**—specifically involving the long arm of chromosome 1—is a frequent **secondary chromosomal abnormality** found in M3. While t(15;17) is the primary driver, these additional changes on chromosome 1 are highly characteristic of the M3 subtype compared to other AMLs. **Analysis of Options:** * **Option B (Correct):** AML-M3 is the correct answer because del(1) or der(1) is a recognized recurrent secondary cytogenetic finding in this subtype. * **Option A (M5):** Monocytic leukemia is typically associated with abnormalities involving **11q23** (*KMT2A/MLL* gene) [1]. * **Option C (M6):** Erythroleukemia is often associated with complex karyotypes, frequently involving deletions of **chromosomes 5 and 7** (-5/del(5q) and -7/del(7q)). * **Option D (M7):** Megakaryocytic leukemia is most commonly associated with **t(1;22)(p13;q13)**, especially in infants, or trisomy 21 in Down Syndrome patients. **High-Yield Clinical Pearls for NEET-PG:** * **M3 Hallmark:** t(15;17) resulting in the *PML-RARA* fusion protein [1]. * **Morphology:** Presence of **Auer rods** (often in bundles called **Faggot cells**) [1]. * **Clinical Emergency:** High risk of **DIC (Disseminated Intravascular Coagulation)** due to the release of procoagulants from granules. * **Treatment:** Highly responsive to **ATRA** (All-trans retinoic acid) and Arsenic Trioxide, which induce differentiation of promyelocytes [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 620-622.

Question 1168: What is the most common subtype of ALL (Acute Lymphoblastic Leukemia)?

A. Pre B cell ALL (Correct Answer)
B. Pre T cell ALL
C. T cell ALL
D. B cell ALL

Explanation: **Explanation:** **Acute Lymphoblastic Leukemia (ALL)** is the most common malignancy in children [2]. It is broadly categorized into B-cell lineage (B-ALL) and T-cell lineage (T-ALL) based on the origin of the lymphoblasts [1]. 1. **Why Pre-B cell ALL is correct:** Approximately **80-85%** of all ALL cases are of B-cell lineage. Within this group, the **Pre-B cell subtype** (specifically the Early Pre-B or "Common" ALL) is the most frequent. These cells typically express markers such as **CD19, CD10 (CALLA), and TdT**. The high prevalence of this subtype in the pediatric population makes it the most common overall. 2. **Analysis of Incorrect Options:** * **Pre-T cell ALL / T-cell ALL (Options B & C):** These account for only **15-20%** of ALL cases. They typically present in adolescent males as a mediastinal mass (thymic involvement) and are often associated with a higher white cell count and a more aggressive clinical course compared to B-ALL [1]. * **B-cell ALL (Option D):** While "B-cell ALL" is a general category, in strict FAB classification (L3), Mature B-cell ALL (Burkitt-type) is rare, accounting for less than 5% of cases [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Most common age group:** 2–5 years [2]. * **Best Prognostic Marker:** Hyperdiploidy (>50 chromosomes) and t(12;21) [2]. * **Poor Prognostic Marker:** t(9;22) (Philadelphia chromosome), which is more common in adults with ALL [2]. * **Immunohistochemistry:** **TdT** is a highly specific marker for lymphoblasts (both B and T), helping distinguish ALL from AML. * **Sanctuary Sites:** The CNS and Testes are common sites of relapse as systemic chemotherapy often fails to penetrate these areas effectively. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 599-600. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 600-602. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 605-606.

Question 1169: Which inherited coagulation defect is characterized by prolonged coagulation time?

A. Protein C deficiency
B. Protein S deficiency
C. Antithrombin III deficiency
D. All of the above (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. All of the above.** This question tests the understanding of the physiological role of natural anticoagulants. In the clinical laboratory, "coagulation time" (and specific assays like PT or aPTT) measures the time it takes for a fibrin clot to form. However, in the context of **inherited thrombophilia**, deficiencies in natural anticoagulants lead to a **prothrombotic (hypercoagulable) state** [1]. **Why the correct answer is right:** * **Protein C and Protein S:** These are Vitamin K-dependent proteins. Activated Protein C (with Protein S as a cofactor) proteolytically inactivates Factors **Va and VIIIa**. A deficiency in either leads to unregulated thrombin generation [1]. * **Antithrombin III (ATIII):** This is a potent inhibitor of thrombin (IIa), IXa, Xa, XIa, and XIIa. Its activity is significantly enhanced by heparin. A deficiency removes a major "brake" on the coagulation cascade. **Note on "Prolonged Coagulation Time":** In these inherited defects, the *in vivo* tendency is towards thrombosis. However, the question refers to the physiological defect where the regulatory mechanisms that normally *limit* or *control* the duration and extent of coagulation are impaired, leading to an overall pathological persistence or excess of coagulation activity [1]. **Clinical Pearls for NEET-PG:** * **Factor V Leiden:** The most common inherited cause of hypercoagulability (due to resistance to activated Protein C) [1]. * **Warfarin-Induced Skin Necrosis:** Classically associated with **Protein C deficiency** due to the short half-life of Protein C compared to other clotting factors. * **Heparin Resistance:** Patients with **Antithrombin III deficiency** may not show the expected prolongation of aPTT when given standard doses of heparin, as heparin requires ATIII to function. * **Virchow’s Triad:** Remember that these inherited defects fall under the "Hypercoagulability" arm of the triad. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 133-134.

Question 1170: Which of the following features characterize Hemolytic Uremic Syndrome?

A. Microangiopathic hemolytic anemia, decreased LDH, Thrombocytopenia
B. Microangiopathic hemolytic anemia, Renal failure
C. Microangiopathic hemolytic anemia, Thrombocytopenia, Renal failure (Correct Answer)
D. Decreased LDH, Thrombocytopenia, Renal failure

Explanation: **Explanation:** Hemolytic Uremic Syndrome (HUS) is a clinical syndrome characterized by a classic **triad**: 1. **Microangiopathic Hemolytic Anemia (MAHA):** Non-immune hemolysis caused by mechanical destruction of RBCs as they pass through fibrin-rich microthrombi, leading to **schistocytes** (helmet cells) on peripheral smear [2]. 2. **Thrombocytopenia:** Consumption of platelets in the formation of microthrombi [2]. 3. **Acute Renal Failure:** Predominant involvement of the renal microvasculature leading to azotemia and oliguria [1]. **Why the correct answer is right:** Option C accurately lists all three components of the HUS triad. The underlying pathophysiology involves endothelial injury (often triggered by Shiga toxin from *E. coli* O157:H7), which leads to localized platelet activation and microvascular thrombosis, primarily in the kidneys [1]. **Analysis of incorrect options:** * **Options A & D:** These are incorrect because HUS is characterized by **increased LDH** (Lactate Dehydrogenase). LDH is an intracellular enzyme released during RBC destruction; its elevation is a hallmark of hemolysis. * **Option B:** While it includes MAHA and Renal failure, it is incomplete as it omits **Thrombocytopenia**, which is a defining diagnostic feature [2]. **High-Yield NEET-PG Pearls:** * **TTP vs. HUS:** Thrombotic Thrombocytopenic Purpura (TTP) presents with a **pentad** (Triad of HUS + Fever + Neurological symptoms) [3]. TTP is usually due to **ADAMTS13 deficiency** [3]. * **D+ HUS:** The most common form (Diarrhea-associated), typically following a gastrointestinal infection with Shiga-like toxin-producing bacteria [1]. * **Lab Findings:** Increased indirect bilirubin, decreased haptoglobin, negative Coombs test, and presence of schistocytes. PT/aPTT are usually **normal** (unlike DIC) [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Kidney, pp. 946-947. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 667-668. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Kidney, pp. 947-948.

Practice by Chapter

Anemias: Classification and Approach

Practice Questions

Hemolytic Anemias

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Myelodysplastic Syndromes

Practice Questions

Acute Leukemias

Practice Questions

Chronic Leukemias

Practice Questions

Lymphomas and Lymphoid Neoplasms

Practice Questions

Plasma Cell Disorders

Practice Questions

Bleeding Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free